BioCardia Submits Revised FDA Pre-Submission for Helix Catheter Approval
BioCardia has filed a revised De Novo pre-submission with the FDA seeking approval for its Helix Catheter for cardiac drug and diagnostic delivery.
BioCardia, Inc. (Nasdaq: BCDA) announced Thursday it has completed a revised pre-submission to the U.S. Food and Drug Administration's Center for Devices and Radiological Health, advancing its bid to win regulatory clearance for the Helix Catheter system.
The Sunnyvale, California-based company filed the document under the FDA's Q-Submission program, a formal pathway that allows device makers to seek early agency feedback before a full De Novo application is submitted. The Helix Catheter is designed to deliver therapeutic and diagnostic agents directly to the heart.
Read more MassPay Cuts FX Steps, Offers Direct Local Currency Payouts to 180 Nations →
BioCardia positions itself as a global leader in cellular and cell-derived therapeutics targeting cardiovascular and pulmonary diseases. The Helix device, if cleared, would represent a commercial milestone for the company's cardiac intervention portfolio, which has been advancing through regulatory channels over multiple years.
The De Novo pathway is typically used for novel, low-to-moderate risk medical devices that lack a substantially equivalent predicate on the market, meaning FDA clearance through this route would set a new regulatory classification for the device. The Q-Submission step is intended to reduce uncertainty and streamline the eventual formal review process.
Analysts tracking small-cap medical device companies will likely monitor BioCardia's FDA correspondence timeline closely, as regulatory progress remains a primary catalyst for the stock. Continue reading at GlobeNewswire - Industry News on Financial Services.
